On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Immunic (IMUX) stock fell after the company said it plans to continue its Phase 3 ENSURE program for lead drug IMU-838 in ...

Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at ...

Option chain shows key data for Immunic's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Immunic.

Other Income: $0.4 million for Q2 2024, up from $0.1 million in Q2 2023. Immunic Inc (NASDAQ:IMUX) reported promising preclinical and clinical data for vidofludimus calcium, highlighting its ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...